Why stem cells? Why now?
The leading causes of death in 1900 were mostly infectious/communicable diseases. While the prevalence of most causes has diminished, the largest increases include heart disease (+40%) and cancer (+300%). Granted, this is partly due to doubling life expectancy and a lack of death from other causes. However, given time and resources, scientists and physicians may cure these challenging diseases.
Today, six of the seven leading causes of death are non-communicable diseases (heart disease, stroke, lung diseases, cancer, Alzheimer’s disease and diabetes). Based on the early promise mentioned above, regenerative medicine may be our best hope to solve the great non-communicable diseases of our time, and perhaps the single most transformative medical innovation in a century.
The scientific community has been publishing about the promising and extraordinary benefits of stem cell research for decades. With results that can help cure crippling and sometimes fatal diseases like Alzheimer’s Disease, Parkinson’s Disease, and Heart Disease, stem cells have gained a reputation of being a miracle cure-all. Diseases that have failed to respond to traditional research can often are treated or cured with stem cells. But with all the years of research and benefits, stem cell research treatments are still not widely available on the medical market.
We believe that our organization: StemCell Research Institute Corp (SCRIC) is a significant contribution we made in the future for helping all of companies in medical field, hospitals, clinics,….etc.
SCRIC’s executive management are : Calvin Cao and Dat Nguyen.
Mr. Calvin Cao – Chairman & CEO. He is a founder of StemCell Research Institute Corp. (SCRIC) as an inventor, innovator and Bio-Entrepreneur, his strategy and commitment to make SCRIC the dominant global company on the market research for the entire field of cell therapy. In 2008, As a chairman and co-founder of Stem Cell Therapy International Corp. He engineered the merger of Stem Cell Therapy International and Histostem of South Korea. Histostem, one of the largest fully accredited cord blood banks in the world, with more than 80,000 cord blood units for use in research and treatments. The successful merger has formed one of the first fully merged Pacific Rim stem cell companies and cord blood repositories with a U.S. entity Amstem Corp.
Dr. Dat Nguyen – President & CEO
He graduated his doctorate of medicine in FRANCE (Faculté Médecine Paris Descartes).
He is obtained his PhD of science and economics and his MBA of strategy & management.
He was a financial manager and businessman, working in the banking and financial domain for more than 30 years.
There were also high-level advisor/consultant in the banking and financial institutions on the strategy, the change and the commercial development.